All posts by imreal

Though They May Seem Simple, These Tales Speak to the Soul


News Image

For those who aren’t into reading a lot, the short stories are easy reading and can be read one or a few at a time and picked up later for more

Author Glenda L Emigh explores a wide range of human emotions through a collection of short stories she has entitled For Now That Is Enough ($15.49, paperback, 9781662875700; $6.99, e-book, 9781662875717).

From experiences most of us share (like the childhood fear of getting a shot) to the extraordinary few can imagine (such as saving a war orphan), there is something here to speak to all hearts. Readers will even discover which biblical character had a bucket list and where God goes when He is silent.

“For those who aren’t into reading a lot, the short stories are easy reading and can be read one or a few at a time and picked up later for more,” said Emigh.

Glenda L. Emigh contributes eight decades of experience to her writing. Over the years she has trained through a variety of writer’s conferences and independent classes, as well as a correspondence course from the Newspaper Institute of America. Emigh wrote a column called “Bit Parts” for a weekly newspaper, as well as feature articles and occasional hard news, and a ghostwritten story in Guideposts that was included in their hardcover yearly edition. This is her fifth book.

###

Xulon Press, a division of Salem Media Group, is the world’s largest Christian self-publisher, with more than 15,000 titles published to date. For Now That Is Enough is available online through xulonpress.com/bookstore, amazon.com, and barnesandnoble.com.

Share article on social media or email:

People USA is Adding a Critical Tool to the Mental Health Toolkit


“We look to be an effective partner in helping the Columbia County community. We commend Dan Almasi and his team for embracing the value of Peer Services,” Steve Miccio, Chief Executive Officer, People USA.

People USA is adding a Certified Peer Specialist to Columbia County’s mental health clinic located at 325 Columbia St Hudson, NY 12534. Currently, these clinics have social workers, nurses, and psychiatrists that help children and adults with their mental health challenges. Columbia County has added another tool to its behavioral health toolkit – a Peer.

This Certified Peer Specialist will be provided by People USA and embedded in Columbia County’s mental health clinic. The Peer will add to the existing staff to instill hope, support wellness, and demonstrate that recovery is real and does happen. The Peer will utilize trauma-informed techniques to help participants set goals, engage in social events, and connect with community resources. The Peer will also provide support for participants to divert hospitalization after discharge. Ultimately, the Peer will share personal experiences that encourage mental wellness and recovery.

“The Columbia County Department of Human Services is very excited to partner with People USA in bringing peer services to its community mental health center. Seeking help can be a challenging experience, and having a person with lived experience to assist in the process has proven beneficial when it comes to engagement with behavioral health services,’ Daniel S. Almasi, LCSW-R, Director of Community Services, Columbia County.

People USA and Columbia County are using this project to create a more holistic continuum of care together.

“We look to be an effective partner in helping the Columbia County community. We commend Dan Almasi and his team for embracing the value of Peer Services, “Steve Miccio, Chief Executive Officer, People USA.

People USA’s mission is to educate, support, and empower people and communities to understand, manage, and overcome mental health, addiction, and social determinant of health challenges.

Share article on social media or email:

The Future of Crisis Care Isn’t in a Hospital


“We appreciate the McSilver Institute’s investment in researching non-traditional peer models. We look forward to the next step in building practice-based evidence into an evidence-based practice,” Steve Miccio, Chief Executive Officer, People USA.

People USA’s innovative Crisis Stabilization Center model is being evaluated by The McSilver Institute for Poverty Policy and Research at New York University. People USA has established the first-ever peer-run Crisis Stabilization Center. Given its innovation, the McSilver Institute will be conducting an evaluation to better understand the “secret sauce” that makes the Crisis Stabilization Center successful. Furthermore, this project will evaluate the outcomes the individuals served are experiencing.

Behavioral health crisis has been on the rise since before the pandemic and has only increased since 2020. COVID has shown us the difficulty faced by our healthcare system in managing a large influx of new patients. And with mental health challenges on the rise, when an individual is experiencing a mental health or substance use crisis, their first instinct is to go to the hospital, which further burdens the system. In addition, the hospital is often not the best place for someone experiencing a behavioral health challenge, especially a child who can be further traumatized by the experience (currently, 50% of individuals served at the Crisis Stabilization Center are children). That is why People USA has created and implemented a peer-run Crisis Stabilization Center.

“We are excited to partner with People USA on the evaluation of the Crisis Stabilization Center and its effectiveness in providing individuals experiencing a behavioral health crisis with a peer-operated alternative to a hospital setting,” Andrew F. Cleek, Psy.D., Deputy Executive Director, NYU McSilver Institute.

Peers are individuals with lived experience who have personally overcome mental health or substance use challenges. Peers can have a variety of credentials from Licensed Social Workers, Nurses, Certified Peer Advocates, Credentialed Family Advocates, and more.

The Crisis Stabilization Center is a 24/7 community crisis response hub where people of all ages can connect immediately with an integrated team of clinical counselors, peer specialists, and behavioral health professionals. The Center is 100% voluntary. Individuals use the Stabilization Center when they’re experiencing emotional distress, acute psychiatric symptoms, addiction challenges, intoxication, family issues, and other life stressors. Stabilization Center guests have immediate access to whole health assessments, crisis counseling, guest-centered care planning, recovery & wellness education, direct connections to outside services, advocacy, and follow-up to ensure quality care.

“We appreciate the McSilver Institute’s investment in researching non-traditional peer models. We look forward to the next step in building practice-based evidence into an evidence-based practice,” Steve Miccio, Chief Executive Officer, People USA.

People USA’s mission is to educate, support, and empower people and communities to understand, manage, and overcome mental health, addiction, and social determinant of health challenges.

The McSilver Institute for Poverty Policy and Research at New York University is committed to disrupting generational poverty through research, policy, and action.

Share article on social media or email:

Hammes Ranked as Top Developer in 2023 Outpatient Healthcare Real Estate Development Report


News Image

Last year, we led the development of a wide range of outpatient projects, including cancer centers, orthopedic centers, surgery centers, freestanding emergency departments, and multi-specialty outpatient centers and medical office buildings, all of which bring critical care closer to patients.

Hammes has been ranked as the nation’s No. 1 developer in the 2023 Outpatient Healthcare Real Estate Development Report. The annual report, produced by healthcare real estate data firm Revista and Healthcare Real Estate Insights (HREI) magazine, measures development activity based on the total square footage of outpatient projects started or completed in a calendar year.

“Last year, we led the development of a wide range of outpatient projects, including cancer centers, orthopedic centers, surgery centers, freestanding emergency departments, and multi-specialty outpatient centers and medical office buildings, all of which bring critical care closer to patients,” said Todd Kibler, Principal of Hammes Partners. “We are honored that healthcare providers continue to turn to Hammes for these strategic outpatient development projects.”

In 2022, Hammes was responsible for 12 outpatient development projects throughout the country, ranging in size and scale.

About Hammes

Founded in 1991, Hammes is a vertically integrated real estate solutions platform specializing in healthcare real estate strategy and planning, project management, development, investment, and property management. As a testament to our deep healthcare industry experience, Hammes has been recognized as one of the nation’s leading healthcare developers by Modern Healthcare’s Construction & Design Survey for 24 consecutive years—including 19 years as No. 1— and by Revista’s Outpatient Healthcare Real Estate Development Report. Headquartered in Milwaukee, Wisconsin, Hammes provides services through a network of regional offices strategically located across the United States. http://www.hammes.com

Share article on social media or email:

Sober Martial Arts (SMA) Launches First Center in New York City Fusing Medicine and Martial Arts’ Sciences to Battle Addictions, Trauma and Imbalance


“Sober Martial Arts teaches that addictions are forces within the body and mind. People can build the power to balance the addictive forces, while understanding them from a non-judgmental space,” states Sifu Matthew Klein, Founder

Celebrity wellness expert, Kung Fu master and renowned Sober Coach, Sifu (see-fu) Matthew Klein, has teamed with seasoned medical and psychiatric detox experts to launch The Sober Martial Arts (SMA) Wellness and Recovery Center in New York City.

The SMA Center, now open in Manhattan, is a bespoke, luxury treatment program for motivated and discerning clientele, who need to learn a new way to gain authentic power, fight back against addictions, and heal imbalances. The Center adds a new dimension to recovery for addictions and mental imbalances, stretching beyond standard models of body/chemistry and various therapies.

Seeing the body as a series of electrical states, SMA uses martial arts’ positions, intentions, philosophies and movements to create new power in the body, designed to alter internal imbalances that would otherwise be impossible to shift.

Klein has worked with all who want to stabilize and defeat their addictions. Some of his clients also include: NBA players, business leaders, physicians, royalty,

celebrities, athletes and executives with life-threatening dependencies and other imbalances. He states, “Anybody can do SMA. No prior training or level of athleticism is necessary. SMA teaches that addictions are forces within the body and mind. People can build the power to balance the addictive forces, while understanding them from a non-judgmental space.”

SMA’s program has provided successful results for a diverse group of clients. Examples include a global finance tycoon who had nearly drunk himself to death on multiple occasions, who is now “clean” and has improved all health symptoms; and a performing artist with a lifelong pot, booze and cigarette addiction who quit permanently in one week and has never looked back.

“At our center in New York, we are excited to provide new answers and skill sets for those who have hopelessly failed to get clean and those who are clean, yet continue to suffer from challenging personality disorders that hinder the acceleration of their lives and relationships,” said Klein.

Working with Klein, in addition to his certified SMA coaches, are a team of integrated medicine doctors along with Psychiatrist and New York University (NYU) faculty member, Dr Jim Dhrymes. Dhrymes’ field of expertise is addiction medicine, trauma and mental imbalances. He offers traditional and alternative approaches to mental and physical recovery. His methods include comprehensive assessment of symptoms and background, nutrition, exercise, and recommendations for ongoing treatment. Dr. Dhrymes strongly recommends the SMA method for recovery because he believes in the importance of movement, mindfulness and martial arts.

As an addict to alcohol starting at age 9, Klein became sober at 22. Though he was substance-free for decades, it was only through his unique practice of martial arts that he was able to understand and transform the deeply ingrained afflictions of mind, body and emotions.

Klein has 40+ years of martial arts study starting at the age of 4. He is a chi master and Sifu of Wing Chung and achieved black belts in Judo and Jiu Jitsu at the early age of 18. He also teaches Liangong and many healing and regeneration systems and is a certified recovery coach. He has lectured and run wellness clinics globally at the Arts Club and Hale Clinic in London, Soho House and the Carillon hotel in Miami.

Klein teaches that the body is the first key to healing: “We don’t use our bodies properly for healing because we aren’t aware of the joy and power our body can bring,” Klein says. “To the addict or traumatized, the body becomes an object s/he casts away, ignoring its creative wisdom, self-sabotaging toward devastation and destruction. With SMA, the body becomes a sacred ally, to build a communication channel and achieve holistic wellness in all areas.

The SMA Center will offer the following luxury bespoke programs for addiction, recovery and wellness:


  • Dual diagnosis treatment
  • Private mentorships with Sifu Matthew, or a certified SMA coach
  • Mastering all addictions including: mental & emotional states like anxiety, rage, shame, mood disorders, personality disorders, ADHD and more.
  • In or outpatient detox
  • Psychiatric, nutritional & integrative medicine support
  • Aftercare wellness programming for 30 days to 1 year.
  • 24/7 SMA coaching support (never relapse again)
  • SMA alumni events & intensives


SMA now also works with luxury rehab centers to train them in the proprietary SMA method.

As an expert in overcoming addictions and developing the Sober Martial Arts system, Klein is available for interviews and speaking engagements in all matters related to authentic wellness, leadership and overcoming addictions and weaknesses. To learn more about Sifu Matthew Klein and Sober Martial Arts’ offerings, visit sobermartialarts.com.

Share article on social media or email:

New Book Teaches Young People That Though God Sends Us Through Trials, We Never Face Them Alone


News Image

reading about Jesus on our first encounter with him and how the innocent child within us may view him.

Author Wendi Coleman invites children to see their Savior as a companion through their trials in Jesus and Malina Marie ($10.99, paperback, 9781662874345; $4.99, e-book, 9781662874352).

Jesus designed a paradise island and prepared a test for Malina Marie to experience: She must retrieve the Flower of Peace that was stolen by Prince Lu. Accompanied by the lion of Judah, she journeys on to the City of Sorrow and the imminent battle ahead.

Coleman said she was inspired by “reading about Jesus on our first encounter with him and how the innocent child within us may view him.”

Wendi Coleman is a retiree from Canton, OH who has already published a book of poetry. She graduated from Malone University and enjoys writing poems and short stories where Jesus triumphs and makes a difference in people’s lives. Coleman has two adult children and five grandchildren.

###

Xulon Press, a division of Salem Media Group, is the world’s largest Christian self-publisher, with more than 15,000 titles published to date. Jesus and Malina Marie is available online through xulonpress.com/bookstore, amazon.com, and barnesandnoble.com.

Share article on social media or email:

An innovative blend of ancient Hebrew and history of science, new book sheds new light on the authenticity of the biblical account of creation


News Image

Archway announces his entry to the publishing scene with the release of “…And It Was So: How modern science sheds new light on the Biblical account of creation” (published by Archway Publishing), a book supporting the authenticity of the Biblical account of creation.

In this book, Ransom argues that perceived gaps between science and the Biblical account of creation stem from misinterpretation. A proper understanding of the Hebrew language, knowledge of the audience for which Genesis was written and the process of Biblical translation, and the nature of science coalesce into a coherent picture of creation in which science and the Bible align.

Ransom takes the reader into the story of creation and the science behind it, distilling complex scientific concepts into easily digestible nuggets, and along the way introduces many of the lesser-known heroes of scientific discovery. In the end, the reader will have a new appreciation for both science and the Bible as well as the harmony that exists between both.

“Many people of faith feel that science is at odds with that faith. Others feel the Biblical account of creation must just be a myth given its apparent contradictions to what we know from science. This book bridges both belief systems and shows that the Genesis account of creation aligns with what science has oncovered in the last few years,” Ransom says. When asked what he wants readers to take away from the book, he answered, “That science is not the enemy of faith and that the creation account in the Bible is not merely a church myth.” For more details about the book, please visit https://www.archwaypublishing.com/en/bookstore/bookdetails/833604-and-it-was-so

“…And It Was So: How modern science sheds new light on the Biblical account of creation”

By Dr. Scott Ransom

Hardcover | 6 x 9in | 484 pages | ISBN 9781665730440

Softcover | 6 x 9in | 484 pages | ISBN 9781665730457

E-Book | 484 pages | ISBN 9781665730464

Available at Amazon and Barnes & Noble

About the Author

Dr. Scott Ransom has worked in the biomedical device industry for over 30 years, helping develop cardiac and neurotechnology devices around the world. He is also faculty at the University of Washington in Seattle, where he has taught and helped numerous student teams develop ideas into lifesaving technologies while working alongside engineers, scientists, and physicians. He is currently Director of Innovation at the Center for Neurotechnology, and a consultant for the National Science Foundation and National Institutes of Health. He has been an AWANA leader for over 25 years and taught hundreds of hours of Sunday school for adults and children alike. He lives with his wife and family in the Seattle area.

Simon & Schuster, a company with nearly ninety years of publishing experience, has teamed up with Author Solutions, LLC, the worldwide leader in self-publishing, to create Archway Publishing. With unique resources to support books of all kind, Archway Publishing offers a specialized approach to help every author reach his or her desired audience. For more information, visit archwaypublishing.com or call 844-669-3957.

Share article on social media or email:

Pfizer Chairman and CEO Dr. Albert Bourla to Keynote LABEST at UCLA Luskin Conference Center on May 25, 2023


Dr. Albert Bourla, Chairman and CEO of Pfizer

The biotech ecosystem is a major engine of innovation and growth, and an increasing percentage of research candidates are coming from the biotech sector.

UCLA Technology Development Group (UCLA TDG) announced today that Albert Bourla, Chairman and CEO of Pfizer will be a keynote speaker at the Los Angeles Bioscience Ecosystem Summit ‘23 (LABEST, pronounced L-A Best.). Dr. Bourla joins Daren Tang, United Nations World Intellectual Property Organization Director General (UN WIPO) who will also deliver a keynote address at the event.

“The pandemic heightened our recognition that many of today’s most disruptive global healthcare challenges are too great for any one organization to tackle alone. They require world-class collaboration to fuel game-changing innovation,” said Dr. Bourla. “The biotech ecosystem is a major engine of innovation and growth, and an increasing percentage of research candidates are coming from the biotech sector. At Pfizer, we want to help catalyze this ecosystem to help transform these candidates into medicines and deliver more breakthroughs for more patients more quickly.”

Drawing on his 30 years of experience at Pfizer, Dr. Bourla will discuss the evolution of the research ecosystem in life sciences, the importance of biotech startups and how both academia and large biopharmaceuticals companies can catalyze this ecosystem.

“Biotech is the lifeblood of innovation, and the greater L.A. ecosystem of world-class academic centers, research institutions and bioscience companies is nourishing exciting growth. I am proud to be part of this collaborative network and thrilled by the growing interest LABEST now commands from leaders throughout the biopharma world,” said Arie Belldegrun, Roy and Carol Doumani Chair in Urologic Oncology, UCLA.

For the 5th year Dr. Belldegrun will moderate one of the summit’s most highly anticipated panels: Meet the Leaders in the Business of Life Science. Executives on the prestigious panel include

  • Norbert Bischofberger, President & CEO, Kronos Bio
  • David Chang, President, CEO, and Co-Founder, Allogene
  • Mark Cobbold, MD, PhD, VP Discovery Oncology, Head of Oncology Cell Therapy, AstraZeneca
  • Aamir Malik, Chief Business Innovation Officer, Executive Vice President, Pfizer
  • Dennis J. Slamon, MD, PhD, Director of Clinical/Translational Research, and Revlon/UCLA Women’s Cancer Research Program, Jonsson Comprehensive Cancer Center

LABEST is the premier showcase for bioscience innovation in Southern California. With national and international presenters and attendees and a true collaboration with colleagues from across LA county, LABEST presents promising academic research, entrepreneurial faculty investigators, and local startup companies. The goal is to highlight the vibrant startup ecosystem and to facilitate partnerships between academia, the biopharma industry, entrepreneurs and investors.

UCLA TDG is excited to fill the UCLA Meyer and Renee Luskin Conference Center once again for the 2023 event, which will be held on May 25. Throughout the summit, faculty members present the latest scientific breakthroughs, which may lead to the critical therapies of tomorrow. Leading bioscience translational research programs and startups will be showcased where Southern California Institutions have significant expertise, pioneering research and resource commitments to develop innovative patient therapies.

LABEST INFORMATION #LABEST2023 @UCLATDG

DATE: May 25, 2023

TIME: 8:30am – 7:00pm PT

LABEST OFFICIAL WEBPAGE: https://tdg.ucla.edu/news-events/events/labest-2023

LINK TO 2023 PROMOTIONAL VIDEO: https://www.youtube.com/watch?v=6UbfHQhUePY

REGISTRATION:

https://web.cvent.com/event/f3b8fb91-0d21-4987-8840-cb9899ed0153/regProcessStep1

WHERE: UCLA Meyer and Renee Luskin Conference Center

AGENDA: https://tdg.ucla.edu/sites/default/files/2023-04/LABEST%202023%20Agenda%20v13.pdf

SCHEDULE:

https://tdg.ucla.edu/sites/default/files/2023-04/LABEST%202023%20Schedule%20At-A-Glance%20v02.pdf

KEYNOTE SPEAKERS

  • Dr. Albert Bourla – Chairman and Chief Executive Officer, Pfizer
  • Daren Tang – United Nations World Intellectual Property Organization Director General (UN WIPO)


CONFERENCE HIGHLIGHTS

  • In-person conference taking place at the UCLA Meyer and Renee Luskin Conference Center
  • Fireside chat with UC Regents and UCLA Chancellor
  • 12 Interactive Showcases
  • Los Angeles Startup Ecosystem Showcase, Co-Hosted by the Larta Institute and the Lundquist Institute


LABEST SHORT TALK/PANEL DESCRIPTIONS

  • Panel – LA Hospital Leaders Innovating For Future Success: Moderator Judy Fortin, Chief of Communications for UCLA Health. A panel discussion with Hospital CEOs from our long-standing LABEST partners in the Los Angeles area, covering challenges, accomplishments, and what the future has in store for Hospitals.
  • Showcase – “Accelerating Innovation in Oncology”: Led by Edward B. Garon, MD, MS, Thoracic Medical Oncology.    


UCLA Technology Development Group (TDG) serves as a campus-wide gateway to UCLA innovation, research and entrepreneurship. Our mission is to: -Promote UCLA innovation, research, teaching and entrepreneurship to benefit society -Create economic value to support UCLA’s scholarly and educational missions and the State of California -Lead UCLA’s research community to bring innovation to market

Website: http://tdg.ucla.edu

Thank you to our Innovator Sponsors:

Amgen

Kite, A Gilead Company

Share article on social media or email:

Highmark Health, Allegheny Health Network Celebrate 10th Anniversary Milestone


The foundation and infrastructure we have built at AHN is not only greatly improving the experience of people today, but it will continue to do so for many years to come.

Allegheny Health Network (AHN) and its parent company, Pittsburgh-based Highmark Health, this week are celebrating the 10th anniversary of an historic affiliation that radically altered the Western Pennsylvania health care landscape and created a new national model for the successful integration of a health insurer and hospital system. The affiliation also preserved thousands of local health care jobs and ensured that the hospitals and clinical programs of AHN’s predecessor organization, West Penn Allegheny Health System (WPAHS), would continue to thrive as some of the region’s leading sources of high-quality health services.  

“A decade ago, we promised to do something bold and different – we would transform our industry and build a better, more affordable health care model by uniquely blending the payer and provider experience and creating innovative solutions that enable our patients and members to live their best lives,” said David Holmberg, Highmark Health president and CEO. “We are extremely proud of what our exceptional caregivers and team members at every level have accomplished in the pursuit of that goal, and we are even more excited about the future and everything we will do in the days ahead to continue our momentum and further reinvent health care.”

In 2011, WPAHS and its hospitals (Allegheny General, West Penn, Canonsburg, Allegheny Valley, and Forbes) were struggling financially when Highmark – then primarily in the health insurance business – proposed a strategic affiliation between the two organizations.

After nearly two years of negotiation and regulatory review, the merger was approved by the Pennsylvania Insurance Department on April 29, 2013. Highmark Health would be the new name of the parent company, while its new provider organization would be known as Allegheny Health Network.

That same year, two additional local hospital systems were brought into the fold to become part of AHN. On March 1, 2013, just weeks before the official creation of AHN, the hospital formerly known as Jefferson Regional Medical Center (now AHN Jefferson Hospital, based in Jefferson Hills, Pa.) joined Highmark’s then-unnamed health care delivery system. And on July 9, 2013, Saint Vincent Health System in Erie, Pa., also joined the organization.

Since then, the network has grown dramatically, building six new large-scale multispecialty outpatient facilities (called Health + Wellness Pavilions), four new smaller-scale “neighborhood hospitals,” one full-service 160-bed hospital in Wexford, Pa., and six new cancer centers located throughout Western Pennsylvania, including a new Cancer Institute hub on the campus of Allegheny General Hospital.

In the last decade, AHN has also opened two new obstetrical units, one at Jefferson Hospital in 2014, and one at the new AHN Wexford Hospital, which opened in 2021, and has completed major expansions of the emergency departments at AHN Saint Vincent and Jefferson, among many other investments.

Much of AHN’s expansion was fueled by a billion-dollar, multi-year strategic investment campaign, which was announced by AHN and Highmark Health in October 2017: “We are listening to our patients and members and developing 21st-century care models, programs and facilities that place their health care needs and preferences at the center of everything we do,” Holmberg said at the time.

In 2020, AHN also finalized an affiliation agreement with Grove City Medical Center, bringing the network’s hospital count to 14. In total, AHN now operates more than 300 sites of care, and the network is staffed by more than 22,000 employees and approximately 2,600 credentialed physicians. It annually sees about 3.6 million patients in its physician practices, manages more than 1.7 million outpatient visits, treats more than 330,000 patients in its emergency departments, performs more than 100,000 surgical procedures, and delivers about 8,600 babies. 

“Thanks to the significant investments that Highmark Health has made in AHN over the past 10 years, our communities today have better access to high quality health care and they are stronger economically because of our impact on jobs creation, the purchase of goods and services, and our community giving, ” said James Benedict, AHN president. “We are also advancing the frontier of health care though innovative medical research and robust academic programs that train the next generation of caregivers.  So the foundation and infrastructure we have built at AHN is not only greatly improving the experience of people today, but it will continue to do so for many years to come.”  

Starting in 2020, the organization led the region’s response to the COVID-19 pandemic, a multi-faceted effort that culminated with a series of mass-vaccination clinics that took place at PNC Park, Erie Insurance Arena, DSG corporate headquarters, and many other large venues throughout 2021. In total, more than 500,000 vaccines were delivered in western Pennsylvania by AHN caregivers, and AHN hospitals cared for more than 44,000 COVID patients.

“Our organization’s response to the pandemic required an enormous, unprecedented mobilization of leadership and resources that demonstrated the true value of the AHN-Highmark Health partnership in a very tangible way,” Benedict said. “For instance, Highmark could not have organized such large-scale vaccination events without AHN’s clinical and operational expertise. And AHN couldn’t have done it without Highmark Health’s organizational support and community relationships. But together, we were able to do remarkable, life-saving work, during one of the most challenging public health emergencies of our lifetimes.”

While the first several years of affiliation were spent growing AHN’s clinical footprint and fortifying its operational foundation, the last few years have been dedicated to strengthening the partnership between AHN and Highmark Health, honing the “Living Health” model that seeks to transform health care by leveraging data insights and clinical expertise to deliver better health outcomes, better patient and caregiver experiences, and more equitable access to resources – all while lowering the overall costs of care.

Though Highmark Health and AHN are celebrating the 10th anniversary of their affiliation, both have much longer legacies of community service.  Highmark Inc., which offers Blues-branded health insurance plans in four states, was formed through the merger of Blue Cross of Western Pennsylvania and Pennsylvania Blue Shield, both of which date to the 1930s. And while AHN was the successor to WPAHS – which itself was created in 1999 – many of its member hospitals are more than a century old. The oldest is Bloomfield’s West Penn Hospital, which was chartered on March 18, 1848, and recently celebrated its 175th anniversary.

“There were doubters, especially early on, that an insurer and a health care provider could make it work,” said Donald Whiting, MD, AHN Chief Medical Officer and AHN’s Neurosciences Institute Chair, who has been part of the AHN and WPAHS family for more than two decades. “But this relationship has proven to be an extraordinary success, and one that has allowed AHN to grow and flourish, expanding its leading-edge clinical programs and introducing new, world-class health care resources to so many of the communities we serve.”

NanoFCM Partners with RoosterBio as an Approved Service Provider for Exosome Analysis


“The in-depth knowledge and expertise in EV characterization provided by RoosterBio will allow new and existing EV platforms to thrive in this exciting field.” – Ben Peacock, Head of Research, NanoFCM Co., Ltd.

NanoFCM Co., Ltd today announced that RoosterBio, Inc. a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, development services, cell engineering, and advanced therapy bioprocess solutions, is approved to provide analytical services worldwide using NanoFCM’s NanoAnalyzer.

In this strategic partnership, RoosterBio becomes the first US-based service provider approved by NanoFCM to perform contract analytical services using the NanoAnalyzer platform. RoosterBio has leveraged the NanoAnalyzer in its exosome / extracellular vesicle (EV) analytics workflows for over a year and offers this technology as a stand-alone service as well as integrated within broader exosome process development programs.

In recent years, exosomes have emerged as a powerful new therapeutic modality, and the number of EV-based products in preclinical and clinical development is increasing rapidly. Traditional methods for exosome characterization have been limited to population-level analysis, while conventional flow cytometry lacks the sensitivity required for single nanoparticle analysis. NanoFCM’s NanoAnalyzer instrument has become established as a powerful tool for multiparameter characterization of natural and synthetic nanoparticles at the single-particle level. RoosterBio is routinely applying this technology to accelerate its customers’ path to the clinic as part of a comprehensive suite of analytical methods to characterize the quality, identity, purity, and potency of both native and genetically engineered exosome products.

RoosterBio and NanoFCM will leverage their combined expertise to develop updated protocols, procedures, and expanded analytical capabilities for NanoFCM’s NanoAnalyzer instrument.

“The in-depth knowledge and expertise in EV characterization provided by RoosterBio will allow new and existing EV platforms to thrive in this exciting field” said Ben Peacock, Head of Research for NanoFCM Co., Ltd. “Coupled with innovative technologies like NanoFCM’s NanoAnalyzer these analytical services will drive promising advancement in EV research, therapeutics and prognostics.”

“We are delighted to be selected as an approved provider for state-of-the-art exosome analytical characterization using NanoFCM’s NanoAnalyzer technology,” said Tim Kelly, Chief Executive Officer of RoosterBio. “Exosomes offer extremely high utility as a new therapeutic modality with the potential to address unmet medical needs, but perhaps the biggest obstacle the field faces is the lack of sensitive, quantitative technologies for EV characterization. Together with NanoFCM, we are solving these key challenges and creating the framework for a truly well-characterized EV biologic.”

About RoosterBio

RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and extracellular vesicle (EV) product and process development to fuel the rapid implementation of scalable advanced therapies. Our high-quality hMSCs, bioprocess media, genetic engineering tools, and EV production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing at reduced cost and increased productivity. With optimized, scalable processes, Type 2 Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under 1 year. RoosterBio is driven by client’s success and creating a world where safe and effective regenerative medicines are rapidly developed and widely available on a global scale.

About NanoFCM

Implementing strategies for single particle quantification and cargo detection, NanoFCM provides a versatile and powerful platform with the NanoAnalyzer, a flow cytometry based system for multi-parameter nanoparticle analyses. Precise measurement of elastically scattered light from single nanoparticles allows for high-resolution size distribution, comparable to cryo-electron microscopy, with fast acquisition times of 1-2 minutes also yielding particle concentration data. Fluorescent labelling technologies can be implemented to yield concurrent detection of important cargos such as proteins, nucleic acids and lipids. Global implementation at some of the top research institutions and high-tech enterprises continue to demonstrate the benefits of nano-flow cytometry for particle characterization.

Share article on social media or email: